These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28858981)

  • 21. Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial.
    Oxlund CS; Pareek M; Rasmussen BSB; Vaduganathan M; Biering-Sørensen T; Byrne C; Almarzooq Z; Olsen MH; Bhatt DL
    Am J Med; 2019 Jul; 132(7):840-846. PubMed ID: 30721655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
    Kjeldsen SE; Berge E; Bangalore S; Messerli FH; Mancia G; Holzhauer B; Hua TA; Zappe D; Zanchetti A; Weber MA; Julius S
    Blood Press; 2016; 25(2):83-92. PubMed ID: 26511535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data.
    Aggarwal R; Mirzan H; Chiu N; Steinkamp J
    Clin Res Cardiol; 2018 Jul; 107(7):565-569. PubMed ID: 29480390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
    Weber MA; Bakris GL; Hester A; Weir MR; Hua TA; Zappe D; Dahlof B; Velazquez EJ; Pitt B; Jamerson K
    Am J Med; 2013 Jun; 126(6):501-8. PubMed ID: 23541376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study.
    Xu W; Goldberg SI; Shubina M; Turchin A
    BMJ; 2015 Feb; 350():h158. PubMed ID: 25655523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Hypertension: Which Goal for Which Patient?
    Jarraya F
    Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline characteristics predicting clinical outcomes and serious adverse events in middle-aged hypertensive women: a subanalysis of the SPRINT in women aged <65 years.
    Aydin V; Akici A; Sakarya S; Akman M; Fak AS
    Turk J Med Sci; 2020 Aug; 50(5):1298-1306. PubMed ID: 32490642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex Differences of Patients With Systemic Hypertension (From the Analysis of the Systolic Blood Pressure Intervention Trial [SPRINT]).
    Ochoa-Jimenez R; Viquez-Beita K; Daluwatte C; Zusterzeel R
    Am J Cardiol; 2018 Sep; 122(6):985-993. PubMed ID: 30072129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus.
    Collard D; Brouwer TF; Peters RJG; Vogt L; van den Born BH
    Hypertension; 2018 Dec; 72(6):1337-1344. PubMed ID: 30571235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
    Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
    Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).
    Khan NA; Rabkin SW; Zhao Y; McAlister FA; Park JE; Guan M; Chan S; Humphries KH
    Hypertension; 2018 May; 71(5):840-847. PubMed ID: 29581214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertension, antihypertensive agents and outcomes following renal transplantation.
    Tutone VK; Mark PB; Stewart GA; Tan CC; Rodger RS; Geddes CC; Jardine AG
    Clin Transplant; 2005 Apr; 19(2):181-92. PubMed ID: 15740553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
    Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
    Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood pressure targets for hypertension in people with diabetes mellitus.
    Arguedas JA; Leiva V; Wright JM
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008277. PubMed ID: 24170669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
    Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE; Dahlöf B; Devereux RB; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wan Y
    Hypertension; 2005 Feb; 45(2):198-202. PubMed ID: 15655123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
    Melloni C; Cornel JH; Hafley G; Neely ML; Clemmensen P; Zamoryakhin D; Prabhakaran D; White HD; Fox KA; Ohman EM; Armstrong PW; Roe MT
    Eur Heart J Acute Cardiovasc Care; 2016 Oct; 5(6):443-454. PubMed ID: 26228448
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.